Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

Imetelstat (GRN163L)--telomerase-based cancer therapy.

Röth A, Harley CB, Baerlocher GM.

Recent Results Cancer Res. 2010;184:221-34. doi: 10.1007/978-3-642-01222-8_16. Review.

PMID:
20072842
2.

Telomerase inhibitor Imetelstat (GRN163L) limits the lifespan of human pancreatic cancer cells.

Burchett KM, Yan Y, Ouellette MM.

PLoS One. 2014 Jan 7;9(1):e85155. doi: 10.1371/journal.pone.0085155.

3.

The telomerase inhibitor imetelstat depletes cancer stem cells in breast and pancreatic cancer cell lines.

Joseph I, Tressler R, Bassett E, Harley C, Buseman CM, Pattamatta P, Wright WE, Shay JW, Go NF.

Cancer Res. 2010 Nov 15;70(22):9494-504. doi: 10.1158/0008-5472.CAN-10-0233.

4.

Imetelstat (a telomerase antagonist) exerts off‑target effects on the cytoskeleton.

Mender I, Senturk S, Ozgunes N, Akcali KC, Kletsas D, Gryaznov S, Can A, Shay JW, Dikmen ZG.

Int J Oncol. 2013 May;42(5):1709-15. doi: 10.3892/ijo.2013.1865.

5.

Specific telomere dysfunction induced by GRN163L increases radiation sensitivity in breast cancer cells.

Gomez-Millan J, Goldblatt EM, Gryaznov SM, Mendonca MS, Herbert BS.

Int J Radiat Oncol Biol Phys. 2007 Mar 1;67(3):897-905.

PMID:
17175117
6.

Telomerase template antagonist GRN163L disrupts telomere maintenance, tumor growth, and metastasis of breast cancer.

Hochreiter AE, Xiao H, Goldblatt EM, Gryaznov SM, Miller KD, Badve S, Sledge GW, Herbert BS.

Clin Cancer Res. 2006 May 15;12(10):3184-92.

7.

Effect of telomerase inhibition on preclinical models of malignant rhabdoid tumor.

Hu Y, Bobb D, Lu Y, He J, Dome JS.

Cancer Genet. 2014 Sep;207(9):403-11. doi: 10.1016/j.cancergen.2014.09.002.

PMID:
25441685
8.

Telomerase antagonists GRN163 and GRN163L inhibit tumor growth and increase chemosensitivity of human hepatoma.

Djojosubroto MW, Chin AC, Go N, Schaetzlein S, Manns MP, Gryaznov S, Harley CB, Rudolph KL.

Hepatology. 2005 Nov;42(5):1127-36.

PMID:
16114043
9.

Oligonucleotide conjugate GRN163L targeting human telomerase as potential anticancer and antimetastatic agent.

Gryaznov SM, Jackson S, Dikmen G, Harley C, Herbert BS, Wright WE, Shay JW.

Nucleosides Nucleotides Nucleic Acids. 2007;26(10-12):1577-9.

PMID:
18066830
10.

Telomerase and cancer therapeutics.

Harley CB.

Nat Rev Cancer. 2008 Mar;8(3):167-79. doi: 10.1038/nrc2275. Review.

PMID:
18256617
11.

Effects of a novel telomerase inhibitor, GRN163L, in human breast cancer.

Gellert GC, Dikmen ZG, Wright WE, Gryaznov S, Shay JW.

Breast Cancer Res Treat. 2006 Mar;96(1):73-81.

PMID:
16319992
12.

Telomerase targeted oligonucleotide thio-phosphoramidates in T24-luc bladder cancer cells.

Dikmen ZG, Wright WE, Shay JW, Gryaznov SM.

J Cell Biochem. 2008 May 15;104(2):444-52.

PMID:
18044713
13.

Telomerase inhibitor GRN163L inhibits myeloma cell growth in vitro and in vivo.

Shammas MA, Koley H, Bertheau RC, Neri P, Fulciniti M, Tassone P, Blotta S, Protopopov A, Mitsiades C, Batchu RB, Anderson KC, Chin A, Gryaznov S, Munshi NC.

Leukemia. 2008 Jul;22(7):1410-8. doi: 10.1038/leu.2008.81.

14.

Oligonucleotides and G-quadruplex stabilizers: targeting telomeres and telomerase in cancer therapy.

Crees Z, Girard J, Rios Z, Botting GM, Harrington K, Shearrow C, Wojdyla L, Stone AL, Uppada SB, Devito JT, Puri N.

Curr Pharm Des. 2014;20(41):6422-37. Review.

PMID:
24975605
15.

Lipid modification of GRN163, an N3'-->P5' thio-phosphoramidate oligonucleotide, enhances the potency of telomerase inhibition.

Herbert BS, Gellert GC, Hochreiter A, Pongracz K, Wright WE, Zielinska D, Chin AC, Harley CB, Shay JW, Gryaznov SM.

Oncogene. 2005 Aug 4;24(33):5262-8.

PMID:
15940257
16.

The telomerase template antagonist GRN163L alters MDA-MB-231 breast cancer cell morphology, inhibits growth, and augments the effects of paclitaxel.

Goldblatt EM, Gentry ER, Fox MJ, Gryaznov SM, Shen C, Herbert BS.

Mol Cancer Ther. 2009 Jul;8(7):2027-35. doi: 10.1158/1535-7163.MCT-08-1188.

18.

Telomerase antagonist imetelstat inhibits esophageal cancer cell growth and increases radiation-induced DNA breaks.

Wu X, Smavadati S, Nordfjäll K, Karlsson K, Qvarnström F, Simonsson M, Bergqvist M, Gryaznov S, Ekman S, Paulsson-Karlsson Y.

Biochim Biophys Acta. 2012 Dec;1823(12):2130-5. doi: 10.1016/j.bbamcr.2012.08.003.

19.
20.

The effect of telomerase template antagonist GRN163L on bone-marrow-derived rat mesenchymal stem cells is reversible and associated with altered expression of cyclin d1, cdk4 and cdk6.

Tokcaer-Keskin Z, Dikmen ZG, Ayaloglu-Butun F, Gultekin S, Gryaznov SM, Akcali KC.

Stem Cell Rev. 2010 Jun;6(2):224-33. doi: 10.1007/s12015-010-9124-7.

PMID:
20180048
Items per page

Supplemental Content

Support Center